PACE GARY W 4

What Happened
Gary W. Pace, a director of Cardiff Oncology, purchased 30,000 shares of the company's common stock on June 18, 2026. The reported transaction price was $1.22 per share, for a total purchase value of $36,600. This was a purchase (transaction code P), which is generally viewed as more informative than routine sales but does not by itself indicate the insider's motivation.

Key Details

• Transaction date: June 18, 2026
• Transaction code: P (purchase — open market or private purchase as reported)
• Shares acquired: 30,000 at $1.22 per share; total consideration $36,600
• Shares owned after transaction: Not disclosed in the supplied filing details
• Filing date: June 22, 2026 — filed within the SEC’s 2-business-day Form 4 window (timely)
• No footnotes, 10b5-1 plan, tax-withholding, or other special conditions were indicated in the provided summary

Context
Purchases by directors can be interpreted as a signal of confidence, but one small purchase (here $36.6k) should be considered alongside other insider activity, company fundamentals, and market conditions. This report simply documents the transaction; it does not explain the director’s reasons.